Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study -- At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and …

Working at Vaxcyte is about more than having a job – it’s about building your career as part of a special team committed to scaling beyond what’s possible. Read some of our employees’ …

Based on the body of positive evidence from the VAX-31 and VAX-24 adult Phase 1/2 programs, Vaxcyte believes its carrier-sparing platform has the potential to set a new standard in disease …

Vaxcyte is a clinical-stage vaccine innovation company based in San Carlos, California with the unique ability to rapidly engineer, optimize and manufacture superior, high-fidelity vaccines at …

Feb 25, 2025 · Vaxcyte is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is …

Vaxcyte Job Listings. Open Jobs. Filter By: Location Team. Employment Type. Work Arrangement. Clear Filters. Summer Intern, Procurement. San Carlos, California / Accounting …

At Vaxcyte, we are driven by our: Bold Goal To prevent or treat infections caused by bacterial diseases, such as invasive pneumococcal disease, Group A Strep, periodontitis and Shigella.

Apr 7, 2025 · Vaxcyte VAX-24 Phase 2 Infant Study Results Conference Call. Mar 12, 2025 Jefferies Biotech on the Beach Summit. Mar 11, 2025 . 2:20 PM EDT. Leerink Global …

Mar 31, 2025 · Vaxcyte is advancing the clinical development of its PCV programs with several anticipated key milestones, including: PCV Franchise Adult Indication. VAX-31. Following an …

Mar 4, 2024 · Vaxcyte expects to announce topline safety, tolerability and immunogenicity data from the Phase 2 study primary three-dose immunization series by the end of the first quarter …